<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN">
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=UTF-8">
    <title>Description of Interventions_1</title>
    <link href="data:image/x-icon;base64,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" rel="icon" type="image/x-icon">
    <style>@import "https://fonts.googleapis.com/css?family=Source+Sans+Pro:ital,wgth:0,400;0,700;1,400;1,700";body {  font-family: "Source Sans Pro", sans-serif;  margin: 40px;}@media screen {  #backToTop {    position: fixed;    bottom: 0px;    left: 50%;    transform: translateX(-50%);    border-radius: 4px 4px 0 0;    padding: 4px 12px 4px 12px;    background: #1f3c73;    font-weight: bold;  }  #backToTop a {    color: white;  }}@media print {  #backToTop {    display: none;  }}table {  width: fit-content;  border-collapse: collapse;}th {  font-weight: bold;  background: LightGray;}td, th {  border: 1px solid LightGray;  padding: 8px;  font-size: 14px;  vertical-align: top;}caption {  font-weight: bold;  font-size: large;  text-align: left;  padding: 8px;}h1 {  font-size:38.5px;}h2 {  font-size:31.5px;}h1 small, h3 {  font-size:24.5px;}h2 small, h4 {  font-size:17.5px;}h3 small, h4 small, h5 {  font-size:14px;}h6 {  font-size:11.9px;}a {  color: #002d64;  text-decoration: none;}.byline {  font-weight: bold;  color: #002D64;}.disclaimer {  font-style: italic;}figure, table.analysis {  width: fit-content;  display: block;  margin-block-start: 1em;  margin-block-end: 1em;  margin-inline-start: 40px;  margin-inline-end: 40px;}thead tr td, th, figcaption, caption {  font-weight: bold;  background: LightGray;}span.inserted {  background-color: #e5ffcd;}span.deleted {  background-color: #e5ffcd;  text-decoration: line-through;}span.marker-yellow {  background-color: #ffff80;}ol ol {  list-style-type: lower-alpha;}ol ol ol {  list-style-type: lower-roman;}</style>
  </head>
  <body>
    <div class="logo">
      <svg xmlns="http://www.w3.org/2000/svg" height="57" viewBox="0 0 1138.5 192" width="338" xml:space="preserve">
        <path d="M86 .5v33a63.3 63.3 0 0 0 0 125v33a96 96 0 0 1 0-191zM106 .5v33a63.3 63.3 0 0 1 0 125v33a96 96 0 0 0 0-191z" fill="#1f3c73"></path>
        <path d="M93 0h6v192h-6z" fill="#a53995"></path>
        <path d="M93 0h6v192h-6zM82 44h8v6h-8z" fill="#a53995"></path>
        <path d="M63 58h40v6H63zM69 73h30v6H69zM78 86h36v6H78zM63 100h42v6H63zM60 114h28v6H60zM88 128h15v6H88zM84 140l6 6-6 6-6-6z" fill="#a53995"></path>
        <g aria-label="Cochrane" fill="#1f3c73" stroke-width="3.368">
          <path d="M256.96 82.722q-7.366 0-13.564-3.413-6.198-3.414-9.97-10.06-3.683-6.737-3.683-16.528 0-9.701 3.772-16.528 3.863-6.917 10.15-10.51 6.378-3.682 13.743-3.682 5.66 0 10.15 2.335 4.492 2.246 7.456 5.3l-7.007 8.443q-2.245-2.066-4.76-3.323-2.426-1.347-5.57-1.347-3.952 0-7.275 2.245-3.234 2.246-5.21 6.468-1.886 4.221-1.886 10.15 0 8.982 3.862 14.013 3.863 5.03 10.33 5.03 3.593 0 6.378-1.617 2.874-1.617 5.03-3.863l7.006 8.264q-7.365 8.624-18.953 8.624zM302.86 82.722q-5.659 0-10.689-2.695-4.94-2.784-7.994-7.994-3.054-5.3-3.054-12.665 0-7.456 3.054-12.665 3.054-5.21 7.994-7.905 5.03-2.784 10.689-2.784t10.599 2.784q4.94 2.695 7.994 7.905 3.054 5.21 3.054 12.665 0 7.365-3.054 12.665-3.054 5.21-7.994 7.994-4.94 2.695-10.599 2.695zm0-10.689q4.042 0 6.108-3.413 2.066-3.504 2.066-9.252 0-5.839-2.066-9.252-2.066-3.413-6.108-3.413-4.132 0-6.198 3.413-1.976 3.413-1.976 9.252 0 5.749 1.976 9.252 2.066 3.413 6.198 3.413zM352.98 82.722q-6.198 0-11.228-2.695-4.94-2.784-7.905-7.994-2.874-5.3-2.874-12.665 0-7.456 3.234-12.665 3.233-5.21 8.533-7.905 5.3-2.784 11.408-2.784 4.132 0 7.276 1.347 3.234 1.348 5.749 3.413l-6.198 8.534q-3.144-2.605-6.018-2.605-4.761 0-7.636 3.413-2.784 3.413-2.784 9.252 0 5.749 2.784 9.252 2.875 3.413 7.186 3.413 2.156 0 4.222-.898 2.066-.988 3.773-2.335l5.21 8.623q-3.324 2.874-7.186 4.132-3.863 1.167-7.546 1.167zM375.53 81.644V18.677h13.204v15.45l-.629 7.994q2.515-2.245 5.839-4.131 3.413-1.977 7.904-1.977 7.276 0 10.51 4.85 3.323 4.762 3.323 13.115v27.666h-13.204v-25.96q0-4.85-1.347-6.646-1.258-1.797-4.132-1.797-2.515 0-4.312 1.168-1.796 1.078-3.952 3.144v30.091zM426.82 81.644V37.091h10.779l.898 7.815h.36q2.425-4.491 5.838-6.647 3.413-2.246 6.827-2.246 1.886 0 3.144.27 1.257.18 2.156.628l-2.156 11.408q-1.168-.359-2.336-.539-1.078-.18-2.515-.18-2.515 0-5.3 1.887-2.694 1.797-4.49 6.288v25.869zM471.28 82.722q-6.108 0-9.701-3.862-3.593-3.953-3.593-9.612 0-7.006 5.928-10.959 5.929-3.952 19.133-5.3-.18-2.964-1.796-4.67-1.527-1.797-5.21-1.797-2.785 0-5.659 1.078-2.874 1.078-6.108 2.964l-4.76-8.713q4.221-2.605 8.982-4.222 4.85-1.616 10.06-1.616 8.533 0 13.114 4.94 4.58 4.94 4.58 15.18v25.51h-10.778l-.898-4.581h-.36q-2.784 2.515-6.018 4.132-3.144 1.527-6.916 1.527zm4.491-10.24q2.246 0 3.863-.988 1.706-1.078 3.413-2.785v-7.814q-7.006.898-9.701 2.874-2.695 1.886-2.695 4.491 0 2.156 1.348 3.234 1.437.988 3.772.988zM507.39 81.644V37.091h10.779l.898 5.659h.36q2.874-2.695 6.287-4.671 3.503-2.066 7.995-2.066 7.275 0 10.509 4.85 3.323 4.761 3.323 13.115v27.666h-13.204v-25.96q0-4.85-1.347-6.646-1.258-1.797-4.132-1.797-2.515 0-4.312 1.168-1.796 1.078-3.952 3.144v30.09zM578.71 82.722q-6.378 0-11.498-2.785-5.12-2.784-8.084-7.994-2.964-5.21-2.964-12.575 0-7.276 2.964-12.486 3.054-5.21 7.904-7.994 4.85-2.875 10.15-2.875 6.378 0 10.51 2.875 4.221 2.784 6.287 7.635 2.156 4.76 2.156 10.869 0 1.706-.18 3.413-.18 1.617-.36 2.425h-26.677q.898 4.85 4.042 7.186 3.144 2.246 7.545 2.246 4.761 0 9.612-2.964l4.4 7.994q-3.412 2.335-7.634 3.683-4.222 1.347-8.174 1.347zm-9.88-28.205h16.078q0-3.683-1.796-6.018-1.707-2.426-5.66-2.426-3.053 0-5.479 2.156-2.425 2.066-3.143 6.288z"></path>
        </g>
        <g aria-label="Library" fill="#a53995" stroke-width="3.368">
          <path d="M236.48 168.68v-58.925h7.455v52.547h25.78v6.378zM279.42 168.68v-43.655h7.366v43.655zm3.773-52.637q-2.156 0-3.593-1.258-1.348-1.347-1.348-3.593 0-2.155 1.348-3.503 1.437-1.347 3.593-1.347 2.155 0 3.503 1.347 1.437 1.348 1.437 3.503 0 2.246-1.437 3.593-1.348 1.258-3.503 1.258zM320.82 169.76q-3.054 0-6.378-1.437-3.233-1.527-6.108-4.132h-.27l-.628 4.491h-5.928v-63.955h7.365v17.426l-.18 7.905q2.965-2.605 6.468-4.312 3.593-1.796 7.186-1.796 8.533 0 12.935 6.018 4.401 6.018 4.401 16.168 0 7.455-2.694 12.755-2.605 5.3-6.917 8.084-4.222 2.785-9.252 2.785zm-1.258-6.198q5.39 0 8.893-4.58 3.593-4.672 3.593-12.756 0-7.186-2.695-11.587-2.605-4.491-8.803-4.491-2.784 0-5.659 1.527-2.874 1.527-6.018 4.401v22.905q2.875 2.515 5.66 3.593 2.874.988 5.03.988zM351.19 168.68v-43.655h6.108l.629 7.905h.27q2.245-4.132 5.479-6.558 3.233-2.425 6.916-2.425 2.605 0 4.671.898l-1.437 6.468q-1.078-.36-1.976-.54-.899-.179-2.246-.179-2.784 0-5.838 2.246-2.965 2.245-5.21 7.814v28.025zM390.26 169.76q-5.48 0-9.162-3.234-3.593-3.323-3.593-9.162 0-7.186 6.377-10.959 6.468-3.862 20.39-5.39 0-2.784-.808-5.299-.719-2.515-2.695-4.042-1.886-1.617-5.479-1.617-3.773 0-7.096 1.437-3.324 1.438-5.928 3.234l-2.875-5.12q3.054-1.976 7.456-3.773 4.49-1.886 9.7-1.886 7.995 0 11.588 4.94 3.593 4.851 3.593 13.026v26.768h-6.108l-.63-5.21h-.269q-3.054 2.515-6.736 4.401-3.593 1.886-7.725 1.886zm2.156-5.928q3.144 0 5.928-1.527 2.785-1.527 5.929-4.312v-12.126q-10.87 1.347-15.27 4.042-4.312 2.695-4.312 6.917 0 3.682 2.246 5.39 2.245 1.616 5.479 1.616zM425.47 168.68v-43.655h6.108l.629 7.905h.27q2.245-4.132 5.479-6.558 3.233-2.425 6.916-2.425 2.605 0 4.671.898l-1.437 6.468q-1.078-.36-1.976-.54-.898-.179-2.246-.179-2.784 0-5.838 2.246-2.965 2.245-5.21 7.814v28.025zM459.6 187.45q-1.437 0-2.785-.27-1.257-.269-2.335-.628l1.437-5.839q.719.18 1.617.36.898.269 1.707.269 3.683 0 6.108-2.695 2.425-2.605 3.772-6.647l.988-3.233-17.516-43.745h7.636l8.892 24.163q.988 2.784 2.066 6.018 1.168 3.233 2.156 6.287h.36q.987-2.964 1.886-6.197.898-3.234 1.796-6.109l7.815-24.163h7.186l-16.438 47.248q-1.527 4.312-3.683 7.725-2.066 3.414-5.21 5.39-3.054 2.066-7.455 2.066z"></path>
        </g>
        <g aria-label="Trusted evidence." fill="#1f3c73" stroke-width="3.368">
          <path d="M710.25 61.723V30.141h-10.671v-3.773h25.869v3.773h-10.671v31.582zM728.9 61.723V35.53h3.665l.377 4.743h.162q1.347-2.48 3.287-3.935t4.15-1.455q1.563 0 2.803.54l-.863 3.88q-.646-.216-1.185-.324-.54-.108-1.348-.108-1.67 0-3.503 1.348-1.778 1.347-3.126 4.689v16.815zM755.25 62.37q-4.15 0-6.09-2.587-1.94-2.64-1.94-7.653v-16.6h4.473v16.007q0 3.665 1.132 5.336 1.185 1.67 3.772 1.67 2.048 0 3.611-1.024 1.617-1.078 3.45-3.395V35.53h4.42v26.193h-3.666l-.377-4.096h-.162q-1.832 2.156-3.88 3.45-2.048 1.293-4.743 1.293zM783.76 62.37q-2.803 0-5.336-1.024-2.533-1.078-4.419-2.587l2.21-2.964q1.724 1.347 3.557 2.263 1.832.863 4.15.863 2.587 0 3.88-1.186 1.294-1.24 1.294-2.91 0-1.348-.917-2.264-.862-.916-2.263-1.509-1.348-.647-2.803-1.186-1.832-.7-3.61-1.562-1.78-.917-2.911-2.318-1.132-1.455-1.132-3.665 0-3.18 2.372-5.281 2.425-2.156 6.683-2.156 2.425 0 4.527.862t3.61 2.102l-2.155 2.802q-1.347-1.024-2.803-1.67-1.455-.647-3.18-.647-2.479 0-3.664 1.132-1.132 1.132-1.132 2.64 0 1.24.809 2.049.808.754 2.101 1.347 1.294.539 2.749 1.132 1.886.7 3.719 1.617 1.832.862 3.018 2.371 1.24 1.455 1.24 3.934 0 2.102-1.132 3.88-1.078 1.78-3.234 2.857-2.102 1.078-5.228 1.078zM806.67 62.37q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306V39.141h-3.88V35.8l4.095-.27.54-7.33h3.718v7.33h7.06v3.61h-7.06v14.553q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.509-.216l1.455-.485.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM826.5 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.071-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.562 2.91q-1.67 1.078-3.826 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM851.56 62.37q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V23.35h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61V41.35q-1.67-1.509-3.234-2.102-1.509-.646-3.126-.646-2.101 0-3.826 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.69 1.886 7.384 1.887 2.64 5.336 2.64zM893.92 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743t-1.67-7.33q0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.706 3.341 2.75 3.342 2.75 8.947 0 .7-.055 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.796.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.959 2.156-2.155 2.102-2.587 5.982zM915.97 61.723l-9.432-26.193h4.581l4.959 14.875 1.185 3.88q.647 1.94 1.24 3.827h.216q.592-1.886 1.185-3.827.647-1.94 1.186-3.88l4.958-14.875h4.366l-9.27 26.193zM935.48 61.723V35.53h4.42v26.193zm2.264-31.582q-1.294 0-2.156-.755-.809-.808-.809-2.155 0-1.294.809-2.102.862-.809 2.156-.809 1.293 0 2.101.809.863.808.863 2.102 0 1.347-.862 2.155-.809.755-2.102.755zM957.68 62.37q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V23.35h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61V41.35q-1.67-1.509-3.234-2.102-1.509-.646-3.126-.646-2.101 0-3.826 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.69 1.887 7.384 1.886 2.64 5.335 2.64zM989.26 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743t-1.67-7.33q0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM1005.4 61.723V35.53h3.665l.377 3.773h.162q1.886-1.887 3.988-3.126 2.102-1.294 4.797-1.294 4.15 0 6.036 2.641 1.94 2.587 1.94 7.6v16.6h-4.42V45.715q0-3.665-1.185-5.335t-3.773-1.671q-1.994 0-3.61 1.024-1.563 1.024-3.558 3.018v18.971zM1045.2 62.37q-3.45 0-6.252-1.617t-4.42-4.689q-1.616-3.072-1.616-7.383 0-4.42 1.725-7.492 1.778-3.072 4.635-4.688 2.91-1.617 6.251-1.617 2.587 0 4.42.916 1.886.916 3.233 2.156l-2.263 2.91q-1.132-1.024-2.425-1.67-1.24-.647-2.803-.647-2.371 0-4.258 1.293-1.832 1.24-2.91 3.557-1.024 2.264-1.024 5.282 0 4.473 2.21 7.276 2.263 2.748 5.874 2.748 1.833 0 3.396-.754 1.563-.809 2.748-1.887l1.94 2.965q-1.778 1.563-3.934 2.479-2.156.862-4.527.862zM1068.9 62.37q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.071-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.707 3.341 2.748 3.342 2.748 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.678q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.724-6.036-1.671-2.102-4.743-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM1087.4 62.37q-1.347 0-2.317-.916-.917-.97-.917-2.426 0-1.562.917-2.479.97-.97 2.317-.97 1.294 0 2.21.97.97.916.97 2.48 0 1.455-.97 2.425-.916.916-2.21.916z"></path>
        </g>
        <g aria-label="Informed decisions." fill="#1f3c73" stroke-width="3.368">
          <path d="M699.58 124.7V89.345h4.473V124.7zM713.32 124.7V98.507h3.665l.377 3.773h.162q1.886-1.887 3.988-3.126 2.102-1.294 4.797-1.294 4.15 0 6.036 2.641 1.94 2.587 1.94 7.6v16.6h-4.42v-16.008q0-3.665-1.185-5.335-1.186-1.671-3.773-1.671-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018V124.7zM743.56 124.7v-22.582h-3.557v-3.341l3.557-.27v-4.15q0-3.988 1.832-6.306 1.887-2.371 5.821-2.371 1.24 0 2.371.27 1.132.215 1.995.592l-.97 3.396q-1.456-.647-2.965-.647-3.665 0-3.665 5.066v4.15h5.552v3.61h-5.552V124.7zM768.19 125.35q-3.18 0-5.982-1.617-2.749-1.617-4.474-4.689-1.67-3.072-1.67-7.383 0-4.42 1.67-7.492 1.725-3.072 4.474-4.688 2.802-1.617 5.982-1.617 3.234 0 5.982 1.617 2.749 1.616 4.42 4.688 1.724 3.072 1.724 7.492 0 4.311-1.724 7.383-1.671 3.072-4.42 4.69t-5.982 1.616zm0-3.665q3.395 0 5.443-2.748 2.102-2.803 2.102-7.276 0-4.527-2.102-7.33-2.048-2.802-5.443-2.802-3.341 0-5.443 2.802t-2.102 7.33q0 4.473 2.102 7.276 2.102 2.748 5.443 2.748zM787.21 124.7V98.507h3.665l.377 4.743h.162q1.347-2.48 3.287-3.935t4.15-1.455q1.563 0 2.803.54l-.863 3.88q-.646-.216-1.185-.324-.54-.108-1.348-.108-1.67 0-3.503 1.348-1.778 1.347-3.126 4.689V124.7zM805.91 124.7V98.507h3.665l.377 3.773h.162q1.724-1.887 3.772-3.126 2.048-1.294 4.366-1.294 3.018 0 4.689 1.348 1.724 1.293 2.533 3.664 2.048-2.21 4.15-3.61 2.101-1.402 4.473-1.402 4.042 0 5.982 2.641 1.994 2.587 1.994 7.6v16.6h-4.42v-16.008q0-3.665-1.185-5.335-1.186-1.671-3.665-1.671-2.91 0-6.575 4.042V124.7h-4.42v-16.007q0-3.665-1.185-5.336-1.186-1.67-3.719-1.67-2.91 0-6.575 4.042v18.97zM861.21 125.35q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.071-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.562 2.91q-1.67 1.078-3.826 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.724-6.036-1.671-2.102-4.743-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM886.27 125.35q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V86.33h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61v-13.69q-1.67-1.509-3.234-2.102-1.509-.646-3.126-.646-2.101 0-3.826 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.689 1.886 7.384 1.887 2.64 5.336 2.64zM926.96 125.35q-4.904 0-7.869-3.557-2.964-3.61-2.964-10.132 0-4.258 1.563-7.33 1.617-3.126 4.204-4.796 2.64-1.671 5.605-1.671 2.264 0 3.934.808 1.671.809 3.396 2.21l-.216-4.473V86.33h4.473v38.373h-3.664l-.378-3.072h-.161q-1.51 1.509-3.557 2.64-2.048 1.079-4.366 1.079zm.97-3.719q3.45 0 6.683-3.61v-13.69q-1.67-1.509-3.234-2.102-1.509-.646-3.125-.646-2.102 0-3.827 1.293-1.67 1.24-2.695 3.503-1.024 2.21-1.024 5.228 0 4.689 1.887 7.384 1.886 2.64 5.335 2.64zM958.54 125.35q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743t-1.67-7.33q0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.959 2.156-2.155 2.102-2.587 5.982zM985.01 125.35q-3.45 0-6.252-1.617-2.802-1.617-4.42-4.689-1.616-3.072-1.616-7.383 0-4.42 1.725-7.492 1.778-3.072 4.635-4.688 2.91-1.617 6.251-1.617 2.587 0 4.42.916 1.886.916 3.233 2.156l-2.263 2.91q-1.132-1.024-2.425-1.67-1.24-.647-2.803-.647-2.371 0-4.258 1.293-1.832 1.24-2.91 3.557-1.024 2.264-1.024 5.282 0 4.473 2.21 7.276 2.263 2.748 5.874 2.748 1.833 0 3.396-.754 1.563-.809 2.748-1.887l1.94 2.965q-1.778 1.563-3.934 2.479-2.156.862-4.527.862zM999.23 124.7V98.507h4.42V124.7zm2.264-31.582q-1.294 0-2.156-.755-.809-.808-.809-2.155 0-1.294.809-2.102.862-.809 2.156-.809 1.293 0 2.101.809.863.808.863 2.102 0 1.347-.862 2.155-.809.755-2.102.755zM1019.3 125.35q-2.803 0-5.336-1.024-2.533-1.078-4.419-2.587l2.21-2.964q1.724 1.347 3.557 2.263 1.832.863 4.15.863 2.587 0 3.88-1.186 1.293-1.24 1.293-2.91 0-1.348-.916-2.264-.862-.916-2.263-1.509-1.348-.647-2.803-1.185-1.832-.701-3.61-1.563-1.78-.917-2.911-2.318-1.132-1.455-1.132-3.665 0-3.18 2.371-5.281 2.426-2.156 6.683-2.156 2.426 0 4.528.862 2.101.862 3.61 2.102l-2.155 2.803q-1.348-1.024-2.803-1.671-1.455-.647-3.18-.647-2.479 0-3.664 1.132-1.132 1.132-1.132 2.64 0 1.24.808 2.049.809.754 2.102 1.347 1.294.539 2.749 1.132 1.886.7 3.718 1.617 1.833.862 3.019 2.371 1.24 1.455 1.24 3.934 0 2.102-1.133 3.88-1.078 1.78-3.233 2.857-2.102 1.078-5.228 1.078zM1035.1 124.7V98.507h4.42V124.7zm2.264-31.582q-1.294 0-2.156-.755-.809-.808-.809-2.155 0-1.294.809-2.102.862-.809 2.156-.809t2.101.809q.863.808.863 2.102 0 1.347-.863 2.155-.808.755-2.101.755zM1058.5 125.35q-3.18 0-5.982-1.617-2.749-1.617-4.474-4.689-1.67-3.072-1.67-7.383 0-4.42 1.67-7.492 1.725-3.072 4.474-4.688 2.802-1.617 5.982-1.617 3.234 0 5.982 1.617 2.749 1.616 4.42 4.688 1.724 3.072 1.724 7.492 0 4.311-1.724 7.383-1.671 3.072-4.42 4.69-2.748 1.616-5.982 1.616zm0-3.665q3.395 0 5.443-2.748 2.102-2.803 2.102-7.276 0-4.527-2.102-7.33-2.048-2.802-5.443-2.802-3.341 0-5.443 2.802t-2.102 7.33q0 4.473 2.102 7.276 2.101 2.748 5.443 2.748zM1077.5 124.7V98.507h3.665l.377 3.773h.162q1.886-1.887 3.988-3.126 2.102-1.294 4.797-1.294 4.15 0 6.036 2.641 1.94 2.587 1.94 7.6v16.6h-4.42v-16.008q0-3.665-1.185-5.335-1.186-1.671-3.773-1.671-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018V124.7zM1113.9 125.35q-2.803 0-5.336-1.024-2.533-1.078-4.419-2.587l2.21-2.964q1.724 1.347 3.557 2.263 1.832.863 4.15.863 2.587 0 3.88-1.186 1.293-1.24 1.293-2.91 0-1.348-.916-2.264-.862-.916-2.263-1.509-1.348-.647-2.803-1.185-1.832-.701-3.61-1.563-1.78-.917-2.911-2.318-1.132-1.455-1.132-3.665 0-3.18 2.372-5.281 2.425-2.156 6.683-2.156 2.425 0 4.527.862 2.102.862 3.61 2.102l-2.155 2.803q-1.348-1.024-2.803-1.671-1.455-.647-3.18-.647-2.479 0-3.664 1.132-1.132 1.132-1.132 2.64 0 1.24.808 2.049.809.754 2.102 1.347 1.294.539 2.749 1.132 1.886.7 3.718 1.617 1.833.862 3.019 2.371 1.24 1.455 1.24 3.934 0 2.102-1.133 3.88-1.078 1.78-3.233 2.857-2.102 1.078-5.228 1.078zM1131.9 125.35q-1.347 0-2.317-.916-.917-.97-.917-2.426 0-1.562.917-2.479.97-.97 2.317-.97 1.294 0 2.21.97.97.916.97 2.48 0 1.455-.97 2.425-.916.916-2.21.916z"></path>
        </g>
        <g aria-label="Better health." fill="#a53995" stroke-width="3.368">
          <path d="M699.58 187.95v-35.355h10.509q3.61 0 6.306.862 2.748.863 4.257 2.749 1.563 1.886 1.563 5.012 0 2.64-1.347 4.797-1.294 2.102-3.827 2.91v.216q3.18.592 5.174 2.694 2.048 2.102 2.048 5.767 0 3.45-1.724 5.767-1.671 2.317-4.69 3.449-3.017 1.132-7.005 1.132zm4.473-20.318h5.228q4.527 0 6.521-1.563 1.994-1.563 1.994-4.258 0-3.072-2.101-4.365-2.048-1.294-6.198-1.294h-5.444zm0 16.761h6.144q4.581 0 7.114-1.67 2.533-1.725 2.533-5.282 0-3.288-2.533-4.797-2.479-1.563-7.114-1.563h-6.144zM741.46 188.6q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.072-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.706 3.341 2.75 3.342 2.75 8.947 0 .7-.055 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.796.808zm-8.246-15.845h14.013q0-3.988-1.724-6.036-1.671-2.102-4.743-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM765.28 188.6q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306v-14.498h-3.88v-3.341l4.095-.27.54-7.33h3.718v7.33h7.06v3.611h-7.06v14.552q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.51-.215l1.454-.486.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM782.42 188.6q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306v-14.498h-3.88v-3.341l4.095-.27.54-7.33h3.718v7.33h7.06v3.611h-7.06v14.552q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.51-.215l1.454-.486.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM802.25 188.6q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.072-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.658-1.67 5.013 0 7.707 3.341 2.749 3.342 2.749 8.947 0 .7-.054 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.616-.593 3.072-1.509l1.562 2.91q-1.67 1.078-3.826 1.887-2.102.808-4.797.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.958 2.156-2.156 2.102-2.587 5.982zM818.36 187.95v-26.193h3.665l.377 4.743h.162q1.347-2.48 3.287-3.935t4.15-1.455q1.563 0 2.803.54l-.863 3.88q-.646-.216-1.185-.324t-1.348-.108q-1.67 0-3.503 1.348-1.778 1.347-3.126 4.689v16.815zM847.84 187.95v-38.373h4.42v10.456l-.162 5.39q1.886-1.779 3.934-3.019 2.102-1.293 4.797-1.293 4.15 0 6.036 2.64 1.94 2.588 1.94 7.6v16.6h-4.42v-16.007q0-3.665-1.185-5.336-1.186-1.67-3.773-1.67-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018v18.97zM887.78 188.6q-3.503 0-6.36-1.617-2.856-1.67-4.527-4.743-1.67-3.072-1.67-7.33 0-4.31 1.67-7.383 1.725-3.072 4.42-4.743 2.694-1.67 5.659-1.67 5.012 0 7.706 3.341 2.75 3.342 2.75 8.947 0 .7-.055 1.401 0 .647-.108 1.132h-17.677q.27 4.15 2.587 6.629 2.372 2.48 6.144 2.48 1.887 0 3.45-.54 1.617-.593 3.072-1.509l1.563 2.91q-1.671 1.078-3.827 1.887-2.102.808-4.796.808zm-8.246-15.845h14.013q0-3.988-1.725-6.036-1.67-2.102-4.742-2.102-2.749 0-4.959 2.156-2.155 2.102-2.586 5.982zM909.18 188.6q-3.288 0-5.497-1.94-2.156-1.994-2.156-5.498 0-4.311 3.826-6.575 3.88-2.317 12.234-3.233 0-1.671-.485-3.18-.43-1.51-1.616-2.426-1.132-.97-3.288-.97-2.264 0-4.258.863-1.994.862-3.557 1.94l-1.724-3.072q1.832-1.186 4.473-2.264 2.695-1.131 5.82-1.131 4.797 0 6.953 2.964 2.156 2.91 2.156 7.814v16.061h-3.665l-.377-3.125h-.162q-1.832 1.509-4.042 2.64-2.156 1.132-4.635 1.132zm1.294-3.557q1.886 0 3.556-.916 1.671-.916 3.557-2.587v-7.276q-6.52.808-9.162 2.425-2.587 1.617-2.587 4.15 0 2.21 1.348 3.234 1.347.97 3.287.97zM934.99 188.6q-2.48 0-3.61-1.509-1.079-1.563-1.079-4.42v-33.09h4.42v33.415q0 1.024.377 1.509.377.43.862.43h.377q.216-.053.593-.107l.593 3.341q-.431.216-1.024.324-.593.108-1.509.108zM952.29 188.6q-4.204 0-5.875-2.425-1.616-2.426-1.616-6.306v-14.498h-3.88v-3.341l4.095-.27.54-7.33h3.718v7.33h7.06v3.611h-7.06v14.552q0 2.425.862 3.773.916 1.293 3.18 1.293.7 0 1.51-.215l1.454-.486.863 3.342q-1.078.377-2.372.647-1.24.323-2.479.323zM962.26 187.95v-38.373h4.42v10.456l-.162 5.39q1.886-1.779 3.934-3.019 2.102-1.293 4.797-1.293 4.15 0 6.036 2.64 1.94 2.588 1.94 7.6v16.6h-4.42v-16.007q0-3.665-1.185-5.336-1.186-1.67-3.773-1.67-1.994 0-3.61 1.024-1.564 1.024-3.558 3.018v18.97zM993.9 188.6q-1.347 0-2.317-.916-.917-.97-.917-2.426 0-1.563.916-2.479.97-.97 2.318-.97 1.294 0 2.21.97.97.917.97 2.48 0 1.455-.97 2.425-.917.916-2.21.916z"></path>
        </g>
      </svg>
    </div>
    <h1>Supplementary material 25 to: Daily iron supplementation for prevention or treatment of iron deficiency anaemia in infants, children, and adolescents</h1>
    <p>
      <span class="byline">Rajagopalan K, Hackl L, Pe&ntilde;a-Rosas JP, Garcia-Casal MN, Rizal M, Mehta NH, Roudik M, Islam S, Trumbull-Kennedy MM, Khondakar NR, Franco JVA, Finkelstein JL, Mehta S</span>
      <br>
      <span class="doi"><a href="https://doi.org/10.1002/14651858.CD013227.pub2">https://doi.org/10.1002/14651858.CD013227.pub2</a></span>
    </p>
    <p>
      <span class="disclaimer">The material in this section has been supplied by the author(s) for publication under a Licence for Publication and the author(s) are solely responsible for the material. Cochrane has reviewed this material, but Cochrane has not copyedited, formatted or proofread. Cochrane accordingly gives no representations or warranties of any kind in relation to, and accepts no liability for any reliance on or use of, such material.</span>
    </p>
    <div id="backToTop">
      <a href="#top">Back to top</a>
    </div>
    <h1>Description of Interventions_1</h1>
    <p> 
    </p>
    <div>
      <table>
        <tr>
          <th style="vertical-align: top;">
            <p>Item</p>
          </th><th style="vertical-align: top;">
            <p>Study ID</p>
          </th>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Amirsasan 2024</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>The effect of sumac powder along with ferrous sulfate on blood markers and oxidative stress in young athletic girls with NAID</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>Teenage female volleyball players (aged 15&ndash;18) with non-anemic iron deficiency (serum ferritin &lt;40 ng/mL)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>Sumac was hypothesized to improve iron metabolism by reducing inflammation (hs-CRP) and oxidative stress, enhancing the effects of iron supplementation in athletes</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>Capsules containing:<br> - Ferrous sulfate (50 mg elemental iron)<br> - Sumac powder (1 g)<br> - Placebo (rice flour, 1 g)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <ul>
              <li>Pre- and post-tests including: fitness tests (agility, anaerobic and aerobic power)</li>
              <li>Blood collection for ferritin, Hb, Hct, MCV, hs-CRP, MDA, TAC</li>
              <li>6 weeks of supplementation and training (2 volleyball + 2 fitness sessions/week)</li>
              <li>24-h food recall and dietary standardization</li>
              <li>Blood samples collected at both phases and analyzed with standard clinical kits</li>
            </ul>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Individual capsules taken daily</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>University of Tabriz, Iran; training and testing in the university sports hall</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>Daily for 6 weeks:<br> - 50 mg elemental iron (ferrous sulfate capsule)<br> - 1 g sumac powder (capsule) in combo group<br> - 1 g rice flour (placebo group)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>Comprehensive dietary guidance was given to avoid foods inhibiting or enhancing iron absorption and standardize intake</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>Subjects excluded if they missed &gt;2 training sessions or irregularly consumed supplements</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>Monitored via exclusion criteria (e.g., supplement adherence, training attendance); however, specific adherence rates not reported</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Lal 2024</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Effect of six-week aerobic training, calcium and iron supplementation on resting calcium levels among school-level athletes</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>60 male school-level athletes aged 12&ndash;19 years from a state sports hostel in Himachal Pradesh</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>To determine if aerobic training combined with supplementation (calcium, iron, combo, placebo) significantly affects resting calcium levels in athletes, which may decrease due to intense training and result in mineral deficiencies</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>- Calcium group: 1000 mg Calcium gluconate/day<br> - Iron group: 10 mg Ferrous Sulphate + 1.5 mg Folic Acid/day<br> - Combo group: 1000 mg Calcium gluconate (morning) + 10 mg Ferrous Sulphate + 1.5 mg Folic Acid (evening)<br> - Placebo group: 100 mg sugar-coated ascorbate/day</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>- Pre-, mid-, and post-test blood samples collected (Day 0, 21, 42)<br> - Resting blood samples analyzed using automated biochemistry analyzer (XL-1000)<br> - Six weeks of aerobic training applied to all groups<br> - Statistical analysis via repeated measures ANOVA and post hoc testing using SPSS v23</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Individually administered daily oral supplementation</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>Training at State Sports Hostel, Una, Himachal Pradesh; biochemical tests at IGMC Shimla biochemistry lab</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>Daily for 6 weeks:<br> - Calcium: 1000 mg/day<br> - Iron: 10 mg Ferrous Sulphate + 1.5 mg Folic Acid/day<br> - Combo: Calcium in morning + Iron in evening<br> - Placebo: 100 mg sugar-coated ascorbate/day</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>All participants were informed of procedures and gave written consent; trained technician conducted sample collection; random sampling ensured balanced group assignment</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Long 2024</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Randomized trial of physical activity (PA) and multi-micronutrient supplementation (MMNS) to improve body composition and micronutrient status among South African schoolchildren</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>Schoolchildren aged 6&ndash;12 years in public schools in peri-urban Gqeberha, Eastern Cape Province, South Africa</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>To assess whether PA, MMNS, or their combination improves fat mass (FM), fat-free mass (FFM), and micronutrient status, addressing rising childhood obesity and micronutrient deficiencies in urbanizing African contexts</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>- MMNS supplement: modified MixMe&trade; powder containing micronutrients (e.g., zinc, vitamin D, β-carotene instead of vitamin A)<br> - Placebo powder: identical in packaging and taste<br> - Teaching materials: KaziKidz PA curriculum for teachers<br> - Bioimpedance analyzer (Tanita MC-580), ELISA kits for biomarkers</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>- Cluster RCT across 4 intervention arms: PA only, MMNS only, PA+MMNS, and placebo<br> - Physical measurements and blood samples at 3 time points (baseline, 9 months, 28 months)<br> - Micronutrient assessments: retinol-binding protein, vitamin D, zinc, serum transferrin receptor (sTfR)<br> - Body composition via bioelectrical impedance analysis<br> - Data analyzed via latent growth curve modeling (LGCM)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>- MMNS and placebo administered by classroom teachers<br> - PA intervention supported by trained physical education staff guiding teachers using KaziKidz lesson plans</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Group-based: class-level randomization and implementation of PA lessons; individual daily supplement administration in class</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>Public primary schools in peri-urban areas of Gqeberha, Eastern Cape, South Africa</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>- PA: daily short activity breaks, 1&times; weekly 45&ndash;60 min PE lesson, and 1&times; weekly 45&ndash;60 min dance session<br> - MMNS: daily supplement (dosage per MixMe&trade; spec; includes 4,500 &micro;g β-carotene)<br> - Duration: intervention ran from 2019 to 2021 (with assessments at ~9 months and ~28 months)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>- Supplement formulation modified to include β-carotene instead of vitamin A to target adiposity<br> - PA sessions adapted via the KaziKidz curriculum to the local school environment</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>COVID-19 pandemic caused school closures and disrupted continuous delivery and follow-up; adjustments made post-pandemic to resume follow-up in 2021</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>- Teachers blinded to allocation<br> - Study staff monitored lesson delivery and guided teachers in PA intervention<br> - Supplements administered consistently during school days (5&times;/week)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>Fidelity partially affected by COVID-19 disruptions; initial implementation robust, but follow-up sample dropped from 1,304 (baseline) to 526 (final assessment)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Svensson 2024</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Effect of low-dose iron supplementation (1 mg/kg/day) on early development in breastfed infants</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>Healthy singleton infants born at term (&gt;2500 g) who were exclusively or predominantly breastfed (&gt;50%) at 4 months and not anemic (Hb &gt;10.5 g/dL)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>To evaluate whether daily iron supplementation from 4 to 9 months improves psychomotor development and reduces risk of iron deficiency or anemia at 12 months in a setting of low risk for iron deficiency</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>- Sachets with micronized microencapsulated ferric pyrophosphate (iron) mixed with maltodextrin (for intervention group)<br> - Identical sachets with maltodextrin only (placebo group)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>- Randomized, placebo-controlled, double-blind trial<br> - Daily supplement from 4 to 9 months of age<br> - Development assessed via Bayley Scales of Infant and Toddler Development III at 12, 24, and 36 months<br> - Blood samples taken at 4 and 12 months for Hb, ferritin, and CRP<br> - Adverse events tracked (e.g., GI symptoms); noncompliance defined as returning &ge;25% of sachets</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>Caregivers administered the daily sachet mixed in 10 mL of lukewarm water or breast milk</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Individually administered at home by caregivers</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>Study conducted in outpatient settings in Poland and Sweden; supplement given at home</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>Once daily from age 4 to 9 months (5 months duration)<br> - Dosage adjusted by weight:<br>  - &lt;7 kg: 7 mg/day<br>  - 7&ndash;10 kg: 10 mg/day<br>  - &gt;10 kg: 15 mg/day</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>Dosage tailored based on infant's weight to approximate 1 mg/kg/day</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>Recruitment modified mid-study: halted in Poland and completed in Sweden due to low recruitment pace</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>- Blinded allocation with coded sachets<br> - Sachet return used to monitor compliance<br> - Compliance monitored; &ge;25% returned sachets indicated noncompliance</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>67.6% compliance in iron group, 64.5% in placebo; 90% follow-up at primary outcome (12 months); data from returned sachets assessed</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Csulak 2023</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Iron supplementation trial in young male basketball players with ferritin &lt;100 μg/L</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>Male basketball players aged &lt;19 years with non-anemic iron deficiency (ferritin &lt;100 μg/L), training ~20 h/week in a youth academy</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>To evaluate whether a higher ferritin cut-off (100 μg/L) is appropriate to identify iron deficiency without anemia (IDNA), and if 3-month iron supplementation improves ferritin levels and/or performance in young athletes</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>- Intervention group: Sorbifer durules tablets (320 mg ferrous sulfate) containing 100 mg elemental iron (II) + 60 mg ascorbic acid<br> - Placebo group: Tablets containing 50 mg vitamin C</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>- Randomized, single-blind, placebo-controlled trial over 3 months<br> - Pre- and post-testing: medical history, ECG, echocardiography, laboratory tests (iron panel), body composition (InBody 770), cardiopulmonary exercise testing (CPET)<br> - Nutrition assessed via food frequency questionnaire (FFQ) and dietary counseling<br> - Iron and placebo tablets administered every second day, 2&times; daily</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>Tablets assigned by a dietitian; physicians remained blinded during the study</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Individually administered tablets every second day</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>Hungary &ndash; Semmelweis University and Honv&eacute;d Basketball Academy</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>- Duration: 3 months<br> - Dose: One tablet twice daily every second day</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>Stratified randomization by age group (U15, U16, U18, U19); iron and placebo administered accordingly; dietary advice provided to avoid additional supplementation</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>- Single-blind design (physicians blinded)<br> - Dietary counseling and FFQ to monitor intake<br> - Compliance ensured via stratified and simple randomization; dietitian managed supplementation adherence</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>- 51 athletes randomized (26 iron, 25 placebo)<br> - No dropouts reported; 3-month follow-up completed<br> - Significant increase in ferritin in the iron group; only 15% reached &gt;100 μg/L; no performance improvement detected</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Varea 2023</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Effectiveness of iron supplementation in preventing iron deficiency anaemia in infants</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>3-month-old infants</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"There is evidence that adherence to daily preventive supplementation is low.9,10 In the 1990s, weekly administration was proposed as an alternative for the prevention of anemia. The rationale for such proposal was that intestinal cells are renewed every 5&ndash;6 days and are limited in their ability to absorb iron. In contrast, intermittent iron administration would expose only new epithelial cells to this nutrient and improve absorption efficiency.11 However, most of these studies were focused on pregnant women and children older than 1 year; the evidence in infants was scant"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"Before and after the intervention, a blood sample (3 mL) was collected from the infants, and the following hematological variables were measured: hemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC), using a Coulter counter (Pentra XLR Horiba Medical, France); ferritin, by enzyme immunoassay (Access-Beckman Coulter, Fullerton, USA); and C-reactive protein (CRP), by turbidimetry (BT 3000 Plus Wiener Autoanalyzer). Anemia was defined as follows: Hb &lt; 9.5 g/dL at 3 months of age and &lt; 11.0 g/dL at 6 months of age, ID: ferritin &lt; 12 ng/mL, and IDA: Hb &lt; 11 g/dL and ferritin &lt; 12 ng/mL.15 A possible inflammatory state was considered if CRP was &ge; 5 mg/L, in which case ID was established if ferritin was &lt; 30 ng/mL. At study initiation, the infant&rsquo;s and their family&rsquo;s sociodemographic data were collected. Weight and height were measured on a monthly basis. Z-scores for weight-for-age (W-A), height-for- age (H-A), and weight-for-height (W-H) were developed according to the tables proposed by the World Health Organization.17</p>
            <p>In each health checkup, adverse events (refusal to take it, constipation, vomiting, diarrhea and/or abdominal pain) and adherence to supplementation were recorded, taking into account the information provided by the adult in charge. Adherence was considered high if the infant complied with more than 80% of the prescription, moderate if it was between 50% and 80%, and low if it was less than 50%"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Participants in the iron group received the intervention in the form of an oral solution containing ferrous sulphate</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>Home-based</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>1 mg/ kg/ day on a daily basis with a maximum of 40 mg /d for 3 months</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>"The dosage and administration of the drug were accompanied by instructions and a dosage recording calendar that was adjusted monthly by the pediatrician"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>Adherence to the intervention was assessed; "Regarding adherence to supplementation, 50.6% of the infants with the daily intervention and 57.1% with the weekly intervention had a high level of adherence, with no significant differences between them."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Pongpitakdamrong 2022</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Effect of iron supplementaion in children with ADHD and ID</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"children/adolescents with ADHD and iron deficiency"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"there have been no studies investigating the effect of iron supplementation in children with ADHD and iron deficiency who are concomitantly on stimulant medication"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"Complete blood count and measurement of serum ferritin levels, as well as serum iron levels and total iron-binding capacity...</p>
            <p>participants in both the ferrous and placebo groups were assessed for ADHD symptoms by parents and teachers using 2 parts of the Vanderbilt Attention-Deficit/Hyperactivity Disorder Diagnostic Rating Scales. [<a href="#433992798370355059">1</a>, <a href="#433992856733833089">2</a>] The first part is an 18-item scale encompassing 18 symptoms of DSM-IV criteria for ADHD: the first 9 items include an inattention subscale and the other 9 items a hyperactivity-impulsivity subscale. Each item can be scored on a scale of 0 to 3 (0, never; 1, oc-casionally; 2, often; and 3, very often), with a higher score denoting more severe ADHD. The second part consists of 8 items evaluating the child&rsquo;s academic and behavioral performance. Each item in the second part can be scored on a scale of 1 to 5 (1, excellent; 2, above average; 3, average; 4, somewhat of a problem; and 5, problematic), with a higher score indicating a worse performance. One parent and 1 teacher Vanderbilt Attention-Deficit/Hyperactivity Disorder Rating Scale was obtained per child at each study time point...</p>
            <p>Participants were interviewed for symptoms of rest-less legs syndrome (RLS) at the initial assessment using 2012 Revised International Restless Legs Syndrome Study Group Diagnostic Criteria for RLS.[<a href="#433992894035875715">3</a>]...</p>
            <p>Parents in both groups were interviewed regarding their child's potential side effects, including abdominal pain, nausea, vomiting, constipation, and diarrhea at the end of this study."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>"Participants in the ferrous group received iron in the form of ferrous fumarate.</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>home-based administration</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>"Each capsule contained 200 mg of ferrous fumarate, which is equivalent to 66.5 mg of elemental iron."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>"Participants who weighed #30 kg received 1 capsule of ferrous fumarate per day for 12 weeks, whereas participants who weighed .30 kg re-ceived 2 capsules per day (2&ndash;4 mg of elemental iron/kg/d) for 12 weeks."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>"Compliance was checked and monitored in both groups by using a weekly telephone monitoring and drug count."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"All participants completed the study protocol except 1 participant in the ferrous group, who did not complete the course of ferrous supplement because of being un-able to swallow the capsule. "</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Stelle 2022</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Iron Babies trial: daily iron supplementation in exclusively breastfed Gambian infants</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>Exclusively breastfed rural Gambian infants aged 6&ndash;10 weeks at enrollment</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>To assess if daily iron supplementation improves iron status without negatively impacting exclusive breastfeeding duration or infant growth, especially in settings with high rates of breastfeeding and marginal infant iron status</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>- Iron supplement: 7.5 mg as ferrous sulphate in 0.5 mL of sorbitol solution USP 70%<br> - Placebo: 0.5 mL of sorbitol solution USP 70%</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>- Randomised, placebo-controlled trial<br> - Daily administration of iron/placebo drops for 98 days (~14 weeks)<br> - Weekly questionnaire on feeding practices; daily health monitoring<br> - Anthropometric data (weight, length) collected at baseline and endline<br> - Iron status and adverse events reported in primary analysis (published elsewhere)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>Field assistants administered supplements daily during home visits</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Individually administered in-home oral supplementation</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>Jarra West, Lower River Region, The Gambia</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>- Daily for 98 days (14 weeks)<br> - 7.5 mg/day iron as ferrous sulphate (in 0.5 mL liquid), or matching placebo</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>- Daily supervised administration by trained field assistants<br> - Data collected through regular household visits and digital records (REDCap)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>High fidelity due to direct daily administration by study staff; very few missing data (7 out of 101 infants lacked endline data)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Hoang 2021</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>High fidelity due to direct daily administration by study staff; very few missing data (7 out of 101 infants lacked endline data)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>Schoolchildren aged 6&ndash;9 years from rural areas of Hai Phong City, Vietnam (undernourished, normal weight, or overweight/obese)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>To evaluate the efficacy of MMNS on biomarkers of iron, zinc, and vitamin A status across children with varying anthropometric statuses; addressing widespread micronutrient deficiencies</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>Capsules containing:<br> - 10 mg iron (ferric pyrophosphate)<br> - 10 mg zinc (zinc sulphate and gluconate)<br> - 400 &micro;g vitamin A<br> - Other vitamins: B1, B2, B3, B6, B12, C, D3, E, folic acid<br> - Minerals: copper, iodine, selenium<br> Placebo capsules: lactose and magnesium stearate</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>- Randomised, double-blind, placebo-controlled 22-week trial<br> - 110 school days of supplementation, consumed under teacher supervision<br> - Blood collected at baseline and endline for Hb, MCV, HCT, RDW-CV, serum ferritin, plasma zinc, and plasma retinol<br> - Anthropometry and dietary intake assessed<br> - Ferritin, zinc, retinol adjusted for inflammation (CRP)</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>Teachers administered capsules; staff from National Institute of Nutrition managed logistics and compliance</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Group-based administration in school, under daily supervision by teachers</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>8 primary schools in 2 rural districts of Hai Phong City, Vietnam</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>- One capsule per school day (5&times;/week for 22 weeks = ~110 days)<br> - Mean intakes during study: ~1070 mg of iron and zinc, ~42,800 &micro;g vitamin A</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>Supplement modified from national standard to include 10 mg zinc instead of 4.1 mg</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>n/a</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>- Daily records kept by teachers on capsule intake<br> - Unused blister packs collected and checked<br> - Identical packaging for blinding<br> - Allocation concealment ensured via random coding</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>High adherence: mean of 107 capsules consumed (95.7% compliance); no loss to follow-up</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Zečkanović 2021</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Safety and efficacy of iron syrup on hematological parameters in children with ID</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"iron-deficient children aged nine months to six years"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"We aimed to determine the safety and efficacy of a novel food supplement &gt;Your&lt; Iron Syrup in the replenishment of iron stores and improvement of hematological parameters in iron-deficient children aged nine months to six years."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>"All parents also received counseling on their child&rsquo;s age-appropriate iron-rich diet and were provided a paper-based study diary to enter any modifications implemented to their child&rsquo;s diet, any adverse events (AE) and missed doses of syrup."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"Chil-dren were assessed against inclusion and exclusion criteria and 0.5 mL of capillary blood was sampled...Enrolment visit was followed by an interim follow-up visit 4 weeks (&plusmn;3 days) later and a final follow-up visit after a period of 12-weeks (&plusmn;3 days) of supplementation. At interim follow-up visit, all study products, dispensed at the previous study visit, were collected from the subjects, and compliance to study interventions was calculated."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>parents provided supplements</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>syrup</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>home-based supplementation</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>"&gt;Your&lt; Iron Syrup contained 14 mg of elemental iron in the form of branded micronized, microencapsulated ferric iron (Qfer), 0.7 mg of vitamin B6, and 1.25 &micro;g of vitamin B12 as active ingredients per 5 mL of the product. Placebo syrup did not contain any iron but was otherwise exactly matched in composition to &gt;Your&lt; Iron Syrup."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>"At enrolment, each child&rsquo;s weight was recorded to determine the required amount of syrup (1 mg of elemental iron per kg of body weight) to be dispensed to last until the next scheduled study visit"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>"At follow up visit, the dose of syrup was modified in response to weight change."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"The mean compliance in both arms was 92% according to recorded missed doses of syrup in the study diaries. There were no statistically significant differences in reported compliances between the two study arms (p = 0.85) compared by an independent samples t-test... Of the participants, 80% were 100% compliant and 97% were at least 80% compliant with the intervention, without significant differences between the arms."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Tohidi 2021</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Effects of Iron Supplementation on ADHD in children</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"50 children with ADHD, aged 5 to 15 years old, who were referred to the child psychiatric clinic of Rasht Shafa Hospital"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"Even though serum ferritin levels are associated with ADHD susceptibility [<a href="#433466498575494129">4</a>], the use of iron as comple-mentary medicine in improving symptoms of this disorder needs further investigation, especially despite contra-dictory results. "</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>"CPRS questionnaire [<a href="#433466552684637172">5</a>] was applied for all subjects, a 48-items questionnaire that employed a 4-point Likert scale. Higher score in this measure indicate higher severity of the disease. This questionnaire provides a qualitative and quantitative assessment of attention deficit hyperactivity symptoms on five different subscales including conduct problems, learning problems, psychosomatic, impulsive-hyperactive, and anxiety. It also contains Hyperactivity Index (HI) which is more sensitive to demonstrate the treatment effect."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"CPRS... was completed by parents in the first, sixth, and twelfth weeks."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>"All subjects took a capsule daily in the morning."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>Home-based administration</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>Rasht Shafa Hospital</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>"... all patients were under the treatment of short-acting form of methylphenidate (Ritalin-by Novartis Pharmaceuticals Corporation) and methylphenidate was matched in both groups in terms of dosage and duration, before entering the study... The first group received iron supplementation (ferrous sulfate 300 mg capsule contain-ing 80 mg of elemental iron) and the second group re-ceived placebo, for 12 weeks."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring<br>  
            </p>
          </td><td style="vertical-align: top;">
            <p>"The treatment in almost all patients were started as soon as they were diagnosed and the dose of methylphenidate had started with 0.3 mg/kg/dose and titrated to the optimal dose that was 20 mg/day in most cases in the time of the study."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>"... patients were regularly visited every two weeks all over the study, for possible side ef-fects of the drugs, checking vital signs and assessing the compliance of treatment."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"... 3 patients in ferrous sulfate and 6 in the placebo group drop-ped out of the study."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Trial author</p>
          </td><td style="vertical-align: top;">
            <p>Pasricha 2021</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Brief name</p>
          </td><td style="vertical-align: top;">
            <p>Iron interventions in infants in rural Bangladesh</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Recipient</p>
          </td><td style="vertical-align: top;">
            <p>"8-month-old children in rural Bangladesh"</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Why</p>
          </td><td style="vertical-align: top;">
            <p>"... there is inad-equate high-quality evidence regarding the benefits and safety of such interventions as a public health strategy for children in low-to-middle-income countries. We aimed to determine whether iron interventions... in infants produce meaningful beneficial or harmful clinical outcomes and whether iron syrup and multiple micronutrient powders produce differential effects.</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (materials)</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>What (procedures)</p>
          </td><td style="vertical-align: top;">
            <p>"Assessments of cognitive, behavioral, language, and motor development were conducted, anthropometric variables (crown&ndash;heel length, weight, and head circumference) were measured at least in duplicate by two trained persons, and z scores were calculated with the use of the 2006 WHO Child Growth Standards [<a href="#422245178669295537">6</a>]. Sociodemographic and nutrition data were collected, and home stimulation was assessed with the use of the family care indicators tool [<a href="#433470719307028565">7</a>] at baseline, immediately after completion of the assigned 3-month regimen, and at 9 months after completion. Venous blood samples of up to 3 ml were collected, and hemoglobin levels were measured with a HemoCue 301+ device (HemoCue). Serum was separated and frozen for analysis of ferritin and C-reactive protein levels. "</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Who provided</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>How (mode of delivery; individual or group)</p>
          </td><td style="vertical-align: top;">
            <p>home-based administration, "The iron syrup (purchased from ACME Laboratories) was administered through a syringe marked with the required volume, and the multiple micronutrient powders (donated by Renata) were sprinkled onto complementary foods."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Where</p>
          </td><td style="vertical-align: top;">
            <p>"Rupganj Upazila, Narayanganj District, Bangladesh, a rural area 35 km northeast of Dhaka covering 235 km<sup>2</sup> and comprising approximately 82,000 households. The Upazila is divided into administrative units known as unions, of which we selected three (Rupganj, Golakandail, and Bhulta) for the trial."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>When and how much</p>
          </td><td style="vertical-align: top;">
            <p>"12.5 mg of elemental iron as ferrous sulfate syrup daily plus placebo packets of multiple micronutrient powders that contained maltodextrin alone;... or placebo syrup and placebo packets... taken daily."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Tailoring</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Modification of intervention throughout the trial</p>
          </td><td style="vertical-align: top;">
            <p>&mdash;</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Strategies to improve or maintain intervention fidelity </p>
          </td><td style="vertical-align: top;">
            <p>"During home visits, mothers or caregivers were asked whether the child had symptoms of infection (i.e., diarrhea [defined as at least 3 loose or liquid stools per day], bloody diarrhea, vomiting, fever, or cough or breathing difficulty) and the number of days in the previous week (during the intervention period) or previous 2 weeks (during the follow-up period) that they had occurred. Parents or caregivers could seek medical care for their infant from government or private providers; the receipt of such care was recorded as an unplanned clinic visit."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p>Extent of intervention fidelity</p>
          </td><td style="vertical-align: top;">
            <p>"Among the 3300 children who had undergone randomization, 2885 (87.4%) were assessed for the primary outcome immediately after completion of the assigned 3-month regimen. Loss to follow-up was similar among the trial groups."</p>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;">
            <p> 
            </p>
          </td><td style="vertical-align: top;">
            <p> 
            </p>
          </td>
        </tr>
      </table>
    </div>
    <p> 
    </p>
    <h2>References</h2>
    <ol>
      <li id="433992798370355059">
        <span publication-type="journal"><span person-group-type="author"><span><span>Bard</span> <span>DE</span></span>, <span><span>Wolraich</span> <span>ML</span></span>, <span><span>Neas</span> <span>B</span></span>, <span><span>Doffing</span> <span>M</span></span>, <span><span>Beck</span> <span>L</span></span></span>. <span>The psychometric properties of the Vanderbilt attention-deficit hyperactivity disorder diagnostic parent rating scale in a community population</span>. <span>Journal of Developmental &amp; Behavioral Pediatrics</span> <span>2013</span>;<span>34</span>(<span>2</span>):<span>72-82</span>. [DOI: <a href="https://doi.org/10.1097/DBP.0b013e31827a3a22">10.1097/DBP.0b013e31827a3a22</a>]</span>
      </li>
      <li id="433992856733833089">
        <span publication-type="journal"><span person-group-type="author"><span><span>Wolraich</span> <span>ML</span></span>, <span><span>Bard</span> <span>DE</span></span>, <span><span>Neas</span> <span>B</span></span>, <span><span>Doffing</span> <span>M</span></span>, <span><span>Beck</span> <span>L</span></span></span>. <span>The psychometric properties of the Vanderbilt attention-deficit hyperactivity disorder diagnostic teacher rating scale in a community population</span>. <span>Journal of Developmental &amp; Behavioral Pediatrics. 2013 Feb 1;34(2):83-93.</span> <span>2013</span>;<span>34</span>(<span>2</span>):<span>83-93</span>. [DOI: <a href="https://doi.org/10.1097/DBP.0b013e31827d55c3">10.1097/DBP.0b013e31827d55c3</a>]</span>
      </li>
      <li id="433992894035875715">
        <span publication-type="other"><span person-group-type="author"><span>International Restless Legs Study Group</span></span>. <span>Revised IRLSSG diagnostic criteria for RLS</span>. <span>http://irlssg. org/diagnosticcriteria</span> <span>2012</span>.</span>
      </li>
      <li id="433466498575494129">
        <span publication-type="journal"><span person-group-type="author"><span><span>Oner</span> <span>P</span></span>, <span><span>Oner</span> <span>O</span></span>, <span><span>Azik</span> <span>FM</span></span>, <span><span>Cop</span> <span>E</span></span>, <span><span>Munir</span> <span>KM</span></span></span>. <span>Ferritin and hyperactivity ratings in attention deficit hyperactivity disorder</span>. <span>Pediatrics International. 2012 Oct;54(5):688-92.</span> <span>2012</span>;<span>54</span>(<span>5</span>):<span>688-92</span>. [DOI: <a href="https://doi.org/10.1111/j.1442-200X.2012.03664.x">10.1111/j.1442-200X.2012.03664.x</a>] [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/22591427">22591427</a>]</span>
      </li>
      <li id="433466552684637172">
        <span publication-type="journal"><span person-group-type="author"><span><span>Gianarris</span> <span>WJ</span></span>, <span><span>Golden</span> <span>CJ</span></span>, <span><span>Greene</span> <span>L</span></span></span>. <span>The Conner's Parent Rating Scales: A critical Review of the Literature</span>. <span>Clinical Psychology Review. 2001 Oct 1;21(7):1061-93.</span> <span>2001</span>;<span>21</span>(<span>7</span>):<span>1061-93</span>. [DOI: <a href="https://doi.org/10.1016/S0272-7358(00)00085-4">10.1016/S0272-7358(00)00085-4</a>]</span>
      </li>
      <li id="422245178669295537">
        <span publication-type="journal"><span person-group-type="author"><span>WHO Multicentre Growth Reference Study Group</span>, <span><span>de Onis</span> <span>M</span></span></span>. <span>WHO Motor Development Study: windows of achievement for six gross motor development milestones</span>. <span>Acta Paediatrica</span> <span>2006</span>;<span>95</span>:<span>86-95</span>. [DOI: <a href="https://doi.org/10.1111/j.1651-2227.2006.tb02379.x">10.1111/j.1651-2227.2006.tb02379.x</a>]</span>
      </li>
      <li id="433470719307028565">
        <span publication-type="journal"><span person-group-type="author"><span><span>De Onis</span> <span>M</span></span>, <span><span>Onyango</span> <span>AW</span></span>, <span><span>Van den Broeck</span> <span>J</span></span>, <span><span>Chumlea</span> <span>WC</span></span>, <span><span>Martorell</span> <span>R</span></span></span>. <span>Measurement and standardization protocols for anthropometry used in the construction of a new international growth reference</span>. <span>Food and nutrition bulletin. 2004;25(1_suppl_1):S27-36.</span> <span>2004</span>;<span>25</span>(<span>Supplement 1</span>):<span>27-36</span>. [DOI: <a href="https://doi.org/10.1177/15648265040251S104">10.1177/15648265040251S104</a>] [PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/15069917">15069917</a>]</span>
      </li>
    </ol>
  </body>
</html>
